Shih-Ming Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shih-Ming Chen has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
- Jen-Ai Lee
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
9 shared publications - Ming-Chia Lee
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
8 shared publications - Jann-Yuan Wang
Department of Internal Medicine, National Taiwan University Hospital
6 shared publications Jen-Ai Lee
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan
6 shared publicationsTzu-Rong Peng
Department of Pharmacy, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Tzu Chi University, Hualien, Taiwan
6 shared publicationsMing-Chia Lee
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Department of Pharmacy, New Taipei City Hospital, New Taipei City, Taiwan
5 shared publications
Latest Publications
- 12 October 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 417, 122618
Efficacy of adjunctive mitochondrial modulators for bipolar depression: A comprehensive systematic review and network meta-analysis
- 12 October 2026
- Published by Elsevier in Journal of Affective Disorders
- Vol. 417, 122618
Efficacy of adjunctive mitochondrial modulators for bipolar depression: A comprehensive systematic review and network meta-analysis
- Open Access
- 9 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2291
Statin Use and the Risks of Delirium and Short-Term Mortality in Hospitalized Adults: An Updated Systematic Review and Meta-Analysis
Background/Objectives: Delirium is a common and serious neuropsychiatric complication in hospitalized and critically ill patients and is associated with prolonged hospitalization and increased mortality. Previous meta-analyses found no clear association between statin use and delirium; however, newly published studies and emerging mortality data warrant re-evaluation. Methods: This updated systematic review and meta-analysis extended a previous meta-analysis and re-evaluated the association between statin use and delirium risk. PubMed, Embase, and the Cochrane Library were searched for eligible studies published from January 2022 through October 2025. Study-level estimates were synthesized using random-effects models. Because ORs, RRs, and HRs are not directly interchangeable, the combined synthesis was considered exploratory. Sensitivity analyses included an OR-only dataset, exclusion of the cross-sectional study, REML models with Hartung–Knapp adjustment, and restriction to observational studies reporting multivariable-adjusted ORs. Results: Nineteen studies (5 randomized controlled trials and 14 observational studies) involving 440,737 participants were included. The exploratory combined analysis yielded an OR of 0.79 (95% confidence interval [CI] 0.66–0.95; p = 0.01; I2 = 90%). Results differed by study design: randomized trials yielded a lower pooled point estimate (OR 0.41, 95% CI 0.20–0.82; I2 = 58%), whereas the pooled association among observational studies was not statistically significant (OR 0.86, 95% CI 0.71–1.03; I2 = 91%; p for subgroup difference = 0.04). However, in the three randomized trials contributing to incident delirium, REML with Hartung–Knapp adjustment substantially widened the confidence interval (OR 0.41, 95% CI 0.09–1.86; p = 0.126). In the overall analysis, REML–Hartung–Knapp inference also increased uncertainty (OR 0.79, 95% CI 0.62–1.00; p = 0.047), as did restriction to multivariable-adjusted observational ORs (OR 0.76, 95% CI 0.57–1.01; p = 0.062). In four studies comprising 21,687 participants, statin use was associated with lower 30-day all-cause mortality under the conventional random-effects model (OR 0.52, 95% CI 0.35–0.79; p = 0.002; I2 = 88%); this estimate remained similar under REML with Hartung–Knapp adjustment (OR 0.52, 95% CI 0.32–0.84; p = 0.022). No significant association was observed for delirium-free days. Conclusions: The available evidence suggests a possible association between statin exposure and lower delirium occurrence, but substantial heterogeneity, differences between randomized and observational evidence, and sensitivity to analytic assumptions limit causal interpretation. The findings do not establish statins as a preventive treatment for delirium or prove a mortality benefit. Further adequately powered randomized trials with clearly defined exposure timing and standardized delirium assessment are warranted.
- 9 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2291
Open AccessStatin Use and the Risks of Delirium and Short-Term Mortality in Hospitalized Adults: An Updated Systematic Review and Meta-Analysis
Background/Objectives: Delirium is a common and serious neuropsychiatric complication in hospitalized and critically ill patients and is associated with prolonged hospitalization and increased mortality. Previous meta-analyses found no clear association between statin use and delirium; however, newly published studies and emerging mortality data warrant re-evaluation. Methods: This updated systematic review and meta-analysis extended a previous meta-analysis and re-evaluated the association between statin use and delirium risk. PubMed, Embase, and the Cochrane Library were searched for eligible studies published from January 2022 through October 2025. Study-level estimates were synthesized using random-effects models. Because ORs, RRs, and HRs are not directly interchangeable, the combined synthesis was considered exploratory. Sensitivity analyses included an OR-only dataset, exclusion of the cross-sectional study, REML models with Hartung–Knapp adjustment, and restriction to observational studies reporting multivariable-adjusted ORs. Results: Nineteen studies (5 randomized controlled trials and 14 observational studies) involving 440,737 participants were included. The exploratory combined analysis yielded an OR of 0.79 (95% confidence interval [CI] 0.66–0.95; p = 0.01; I2 = 90%). Results differed by study design: randomized trials yielded a lower pooled point estimate (OR 0.41, 95% CI 0.20–0.82; I2 = 58%), whereas the pooled association among observational studies was not statistically significant (OR 0.86, 95% CI 0.71–1.03; I2 = 91%; p for subgroup difference = 0.04). However, in the three randomized trials contributing to incident delirium, REML with Hartung–Knapp adjustment substantially widened the confidence interval (OR 0.41, 95% CI 0.09–1.86; p = 0.126). In the overall analysis, REML–Hartung–Knapp inference also increased uncertainty (OR 0.79, 95% CI 0.62–1.00; p = 0.047), as did restriction to multivariable-adjusted observational ORs (OR 0.76, 95% CI 0.57–1.01; p = 0.062). In four studies comprising 21,687 participants, statin use was associated with lower 30-day all-cause mortality under the conventional random-effects model (OR 0.52, 95% CI 0.35–0.79; p = 0.002; I2 = 88%); this estimate remained similar under REML with Hartung–Knapp adjustment (OR 0.52, 95% CI 0.32–0.84; p = 0.022). No significant association was observed for delirium-free days. Conclusions: The available evidence suggests a possible association between statin exposure and lower delirium occurrence, but substantial heterogeneity, differences between randomized and observational evidence, and sensitivity to analytic assumptions limit causal interpretation. The findings do not establish statins as a preventive treatment for delirium or prove a mortality benefit. Further adequately powered randomized trials with clearly defined exposure timing and standardized delirium assessment are warranted.
- 31 December 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152908
The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: A systematic review and meta-analysis
- 31 December 2025
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 77, 152908
The efficacy of metformin for pain, function, and quality of life in knee osteoarthritis: A systematic review and meta-analysis
- Open Access
- 31 December 2025
- Published by Elsevier in Integrative Medicine Research
- Vol. 15 (2) , 101286
Concurrent Chinese and Western medication use and risk of acute exacerbations in chronic obstructive pulmonary disease: A national cohort study
- 31 December 2025
- Published by Elsevier in Integrative Medicine Research
- Vol. 15 (2) , 101286
Open AccessConcurrent Chinese and Western medication use and risk of acute exacerbations in chronic obstructive pulmonary disease: A national cohort study
- Open Access
- 11 November 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-12
Effect of n-3 polyunsaturated fatty acids on the treatment of schizophrenia: an updated systematic review and meta-analysis
Background: Schizophrenia is a chronic disorder, and treatment options for its negative and cognitive symptoms are limited. Omega-3 fatty acids have potential neuroprotective effects, but evidence of their efficacy in schizophrenia and ultra-high risk group is inconsistent. This study aimed to provide an updated meta-analysis of randomized controlled trials evaluating the effectiveness of omega-3 fatty acid supplementation in patients with schizophrenia and ultra-high risk group. Methods: A PRISMA-guided meta-analysis of randomized controlled trials comparing omega-3 fatty acids with placebo in schizophrenia was conducted. The literature search was concluded on November 12, 2024, and was conducted without any restrictions on language or timeframe. Data were extracted and analyzed using fixed or random-effects model depending on heterogeneity. Subgroup, sensitivity, and bias assessments were performed. Results: The meta-analysis, which included 16 trials with 1,435 participants, revealed no significant difference between omega-3 fatty acids and placebo in schizophrenia at the endpoint of intervention (standard mean difference = − 0.123; 95% confidence interval = − 0.267 to 0.021; p = 0.095), and ultra-high risk of schizophrenia at the endpoint of follow-up after intervention (standard mean difference = − 0.070; 95% confidence interval = − 0.425 to 0.285; p = 0.699). A small number of subgroup analyses suggested potential benefits for patients with first-episode schizophrenia and treatment over 24 weeks, and those receiving adjunctive antioxidant treatment. Publication bias was minimal. Conclusions: Omega-3 fatty acid supplementation generally has no significant benefits for treating schizophrenia and ultra-high risk group. However, subgroup findings highlight the need for future trials focusing on early-stage patients, longer supplementation, and exploring synergistic effects with adjunctive antioxidant interventions. Clinical application should remain cautious until further confirmatory evidence emerges.
- 11 November 2025
- Published by Springer Nature in BMC Psychiatry
- Vol. 25 (1) , 1-12
Open AccessEffect of n-3 polyunsaturated fatty acids on the treatment of schizophrenia: an updated systematic review and meta-analysis
Background: Schizophrenia is a chronic disorder, and treatment options for its negative and cognitive symptoms are limited. Omega-3 fatty acids have potential neuroprotective effects, but evidence of their efficacy in schizophrenia and ultra-high risk group is inconsistent. This study aimed to provide an updated meta-analysis of randomized controlled trials evaluating the effectiveness of omega-3 fatty acid supplementation in patients with schizophrenia and ultra-high risk group. Methods: A PRISMA-guided meta-analysis of randomized controlled trials comparing omega-3 fatty acids with placebo in schizophrenia was conducted. The literature search was concluded on November 12, 2024, and was conducted without any restrictions on language or timeframe. Data were extracted and analyzed using fixed or random-effects model depending on heterogeneity. Subgroup, sensitivity, and bias assessments were performed. Results: The meta-analysis, which included 16 trials with 1,435 participants, revealed no significant difference between omega-3 fatty acids and placebo in schizophrenia at the endpoint of intervention (standard mean difference = − 0.123; 95% confidence interval = − 0.267 to 0.021; p = 0.095), and ultra-high risk of schizophrenia at the endpoint of follow-up after intervention (standard mean difference = − 0.070; 95% confidence interval = − 0.425 to 0.285; p = 0.699). A small number of subgroup analyses suggested potential benefits for patients with first-episode schizophrenia and treatment over 24 weeks, and those receiving adjunctive antioxidant treatment. Publication bias was minimal. Conclusions: Omega-3 fatty acid supplementation generally has no significant benefits for treating schizophrenia and ultra-high risk group. However, subgroup findings highlight the need for future trials focusing on early-stage patients, longer supplementation, and exploring synergistic effects with adjunctive antioxidant interventions. Clinical application should remain cautious until further confirmatory evidence emerges.
- Open Access
- 20 July 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (7) , e70649
Raloxifene as an Adjuvant Therapy for Patients With Schizophrenia: An Up‐To‐Date Systematic Review and Meta‐Analysis
Background and Hypothesis: Raloxifene may be useful as an adjunctive treatment for schizophrenia, particularly in addressing psychotic symptoms. This meta‐analysis aimed to evaluate the effectiveness and safety of adjunctive raloxifene in improving positive, negative, and general psychopathology symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS). Study Design: A systematic search was performed using PubMed, Embase, and the Cochrane Library databases for articles published until May 2024. Randomized controlled trials investigating the effectiveness and safety of adjunctive raloxifene for treating schizophrenia were included. The primary outcome was psychotic symptom severity using PANSS subscales. Mean differences (MDs) and their 95% confidence intervals (CIs) were calculated using random effects models. Study Results: Ten studies were included in the final analysis. Compared with the placebo group, raloxifene as an adjunctive therapy significantly improved the positive, negative, general, and total PANSS scores, MD = −1.00 (95% CI = −2.00 to −0.20; I 2 = 48%; p = 0.02; τ 2 = 0.87), MD = −1.35 (95% CI = −2.74 to 0.04; I 2 = 71%; p = 0.06; τ 2 = 3.27), MD = −3.29 (95% CI = −5.74 to −0.83; I 2 = 74%; p = 0.009; τ 2 = 9.59), and MD = −7.12 (95% CI = −11.89 to −2.36; I 2 = 74%; p = 0.003; τ 2 = 41.86), respectively. Conclusions: Adjunctive raloxifene appears to be a safe and effective treatment for improving positive, general, and total symptoms in patients with schizophrenia, particularly in those with mild‐to‐moderate illness and postmenopausal women. The 60 mg daily dose over at least 12 weeks yielded the most consistent benefits. Further high‐quality trials are needed to confirm its efficacy across diverse populations and guide personalized treatment strategies.
- 20 July 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (7) , e70649
Open AccessRaloxifene as an Adjuvant Therapy for Patients With Schizophrenia: An Up‐To‐Date Systematic Review and Meta‐Analysis
Background and Hypothesis: Raloxifene may be useful as an adjunctive treatment for schizophrenia, particularly in addressing psychotic symptoms. This meta‐analysis aimed to evaluate the effectiveness and safety of adjunctive raloxifene in improving positive, negative, and general psychopathology symptoms, as measured by the Positive and Negative Syndrome Scale (PANSS). Study Design: A systematic search was performed using PubMed, Embase, and the Cochrane Library databases for articles published until May 2024. Randomized controlled trials investigating the effectiveness and safety of adjunctive raloxifene for treating schizophrenia were included. The primary outcome was psychotic symptom severity using PANSS subscales. Mean differences (MDs) and their 95% confidence intervals (CIs) were calculated using random effects models. Study Results: Ten studies were included in the final analysis. Compared with the placebo group, raloxifene as an adjunctive therapy significantly improved the positive, negative, general, and total PANSS scores, MD = −1.00 (95% CI = −2.00 to −0.20; I 2 = 48%; p = 0.02; τ 2 = 0.87), MD = −1.35 (95% CI = −2.74 to 0.04; I 2 = 71%; p = 0.06; τ 2 = 3.27), MD = −3.29 (95% CI = −5.74 to −0.83; I 2 = 74%; p = 0.009; τ 2 = 9.59), and MD = −7.12 (95% CI = −11.89 to −2.36; I 2 = 74%; p = 0.003; τ 2 = 41.86), respectively. Conclusions: Adjunctive raloxifene appears to be a safe and effective treatment for improving positive, general, and total symptoms in patients with schizophrenia, particularly in those with mild‐to‐moderate illness and postmenopausal women. The 60 mg daily dose over at least 12 weeks yielded the most consistent benefits. Further high‐quality trials are needed to confirm its efficacy across diverse populations and guide personalized treatment strategies.
- 7 November 2024
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 51 (3) , 625-636
The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis
Weight gain and metabolic complications are substantial adverse effects associated with second-generation antipsychotics. However, comprehensive guidelines for managing antipsychotic-induced weight gain are lacking. This review included all double-blind, placebo-controlled studies investigating metformin’s effectiveness in addressing antipsychotic-related weight gain. We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Google Scholar, and ClinicalTrials.gov for relevant studies from the inception to 2024. A random-effects model was used for the meta-analysis. This meta-analysis, including 20 studies with 1070 patients, revealed that metformin significantly surpassed placebo in attenuating weight gain in patients receiving antipsychotics. The mean weight change with metformin was −3.32 kg [95% confidence interval (CI): −4.57 to −2.07]. Additionally, metformin use resulted in a marked decrease in body mass index [−1.24 kg/m2 (95% CI: −1.70 to −0.77)]. Metformin could maintain the effects from 12 to 24 weeks. This updated meta-analysis investigated the durations and dosages of metformin use in patients with schizophrenia experiencing antipsychotic-induced weight gain. The findings highlight the need for additional large-scale research to validate our findings.
- 7 November 2024
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 51 (3) , 625-636
The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis
Weight gain and metabolic complications are substantial adverse effects associated with second-generation antipsychotics. However, comprehensive guidelines for managing antipsychotic-induced weight gain are lacking. This review included all double-blind, placebo-controlled studies investigating metformin’s effectiveness in addressing antipsychotic-related weight gain. We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Google Scholar, and ClinicalTrials.gov for relevant studies from the inception to 2024. A random-effects model was used for the meta-analysis. This meta-analysis, including 20 studies with 1070 patients, revealed that metformin significantly surpassed placebo in attenuating weight gain in patients receiving antipsychotics. The mean weight change with metformin was −3.32 kg [95% confidence interval (CI): −4.57 to −2.07]. Additionally, metformin use resulted in a marked decrease in body mass index [−1.24 kg/m2 (95% CI: −1.70 to −0.77)]. Metformin could maintain the effects from 12 to 24 weeks. This updated meta-analysis investigated the durations and dosages of metformin use in patients with schizophrenia experiencing antipsychotic-induced weight gain. The findings highlight the need for additional large-scale research to validate our findings.
- 3 November 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 91, 151-159
Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis
- 3 November 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 91, 151-159
Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis
- 7 May 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 89, 75-83
Statins as an adjuvant therapy for patients with schizophrenia: An up-to-date systematic review and meta-analysis
- 7 May 2024
- Published by Elsevier in General Hospital Psychiatry
- Vol. 89, 75-83
Statins as an adjuvant therapy for patients with schizophrenia: An up-to-date systematic review and meta-analysis
- 1 October 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 293, 205-213
Effects of various statins on depressive symptoms: A network meta-analysis
- 1 October 2021
- Published by Elsevier in Journal of Affective Disorders
- Vol. 293, 205-213
Effects of various statins on depressive symptoms: A network meta-analysis